Shire scoops up Advanced BioHealing ahead of IPO
This article was originally published in Scrip
Shire has swooped in to acquire Advanced BioHealing for $750 million in cash. The US regenerative medicine firm filed for an IPO worth up to $225 million having priced 13.35 million shares at between $14 and $16 each just a week ago. This implied a post-money valuation of around $560-640 million. Shire's bid thus represents a premium to the pre-money valuation of around 50-70%.